We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.30
Bid: 2.60
Ask: 4.00
Change: 0.25 (8.20%)
Spread: 1.40 (53.846%)
Open: 3.05
High: 0.00
Low: 0.00
Prev. Close: 3.05
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company / PDMR Shareholding

4 Jan 2017 16:36

RNS Number : 3690T
Proteome Sciences PLC
04 January 2017
 

Proteome Sciences plc

(the "Company")

Holdings in Company and PDMR Shareholding

 

Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Sciences Fund ("Vulpes"), of which Martin Diggle, a non-executive director of the Company, is a director and partner, that today, it purchased 105,590 ordinary shares of 1 pence each ("Ordinary Shares") at 5.5 pence per Ordinary Share (the "Transaction"). Following the Transaction, Vulpes (and Mr Diggle) have a beneficial interest in 53,943,715 Ordinary Shares, representing approximately 18.33% of the current issued share capital of the Company.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Vulpes Life Sciences Fund

2.

Reason for the Notification

a)

Position/status

Martin Diggle, non-executive director of the Company is a director and partner of Vulpes Life Sciences Fund

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Proteome Sciences plc

b)

LEI

n/a

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 1p each

Identification code

GB0003104196

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

04 January 2017

Price(s)

Volume(s)

5.5p

105,590

d)

Aggregated information:

· Aggregated volume

· Price

 

105,590 Ordinary Shares of 1 pence each purchased at an average price of 5.5 pence per Ordinary Share

e)

Date of the transaction

04 January 2017

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBLGDBSXGBGRS
Date   Source Headline
10th Apr 20247:00 amRNSFinal Results
2nd Jan 20247:00 amRNSCompletion of new facility in San Diego
30th Nov 20237:00 amRNSTrading Update
2nd Oct 20237:00 amRNSLaunch of Single Cell Proteomics Services
30th Aug 20232:14 pmRNSInvestor Presentation
25th Aug 20237:00 amRNSInterim Results
1st Jun 20239:43 amRNSRepayment of Loan
17th May 20231:05 pmRNSResult of AGM
17th May 20237:00 amRNSAGM Statement
12th May 20237:00 amRNSExpansion into the US
14th Apr 202310:45 amRNSDirector/PDMR Shareholding
6th Apr 202311:34 amRNSDirector/PDMR Shareholding
6th Apr 202310:30 amRNSInvestor Presentation
4th Apr 20237:00 amRNSFinal Results
29th Mar 20237:00 amRNSNotice of Results
6th Mar 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20237:00 amRNSTrading Update
5th Jan 20237:00 amRNSMilestone Payment for TMT®/TMTpro™ Sales
1st Dec 20224:38 pmRNSGrant of Options and PDMR/director shareholdings
12th Oct 20227:00 amRNSGrant of Options and PDMR/director shareholdings
4th Oct 20227:00 amRNSChange of Auditor
20th Sep 20224:40 pmRNSSecond Price Monitoring Extn
20th Sep 20224:35 pmRNSPrice Monitoring Extension
18th Aug 20227:00 amRNSAppointment of Chief Financial Officer
11th Aug 20227:00 amRNSInvestor Presentation
4th Aug 20227:00 amRNSInterim Results
3rd Aug 20227:00 amRNSMilestone towards Single Cell Proteomics services
26th May 20229:04 amRNSChange of Registered Office
16th May 20221:24 pmRNSResult of AGM
16th May 20227:00 amRNSAGM Statement
12th May 20227:00 amRNSSubstantial Contract Win
26th Apr 20224:45 pmRNSDirector/PDMR Shareholding
21st Apr 20225:13 pmRNSDirector/PDMR Shareholding
11th Apr 20227:00 amRNSInvestor Presentation
1st Apr 20226:01 pmRNSDirector shareholding
31st Mar 20227:09 amRNSFinal Results
30th Mar 202211:24 amRNSLoan amendment
29th Mar 20227:00 amRNSNotice of Results
16th Feb 20224:40 pmRNSSecond Price Monitoring Extn
16th Feb 20224:35 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSTrading Update
31st Dec 202112:36 pmRNSPrice Monitoring Extension
20th Dec 20217:00 amRNSSubstantial Contract Win
9th Dec 20214:41 pmRNSSecond Price Monitoring Extn
9th Dec 20214:36 pmRNSPrice Monitoring Extension
29th Nov 20214:36 pmRNSPrice Monitoring Extension
26th Nov 20214:36 pmRNSPrice Monitoring Extension
5th Nov 20217:00 amRNSPRM,INmune Bio presenting biomarker discovery data
3rd Nov 20214:41 pmRNSSecond Price Monitoring Extn
3rd Nov 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.